Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
BACKGROUND
The preclinical experiments and several clinical studies showed icotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in Chinese patients with advanced non-small cell lung cancer (NSCLC) who failed previous chemotherapy. We performed a retrospective study of the efficacy and safety of icotinib monotherapy in a different and more recent sample of Chinese patients.


METHODS
The clinical data of 149 patients with advanced NSCLC who were admitted to Zhejiang Cancer Hospital from August 1, 2011 to July 31, 2012 were retrospectively analyzed. All patients were given icotinib treatment after the failure of previous chemotherapy. Univariate and multivariate analyses were conducted based on the Kaplan Meier method and Cox proportional hazards model.


RESULTS
The objective response rate was 33/149 and disease control rate was 105/149. No complete response occurred. Median progression free survival (PFS) with icotinib treatment was 5.03 months (95% CI: 3.51 to 6.55). Median overall survival was 12.3 months (95% CI: 10.68 to 13.92). Multivariate analysis showed that the mutation of EGFR and one regimen of prior chemotherapy were significantly associated with longer PFS. At least one drug related adverse event was observed in 65.8% (98/149) of patients, but mostly grade 1 or 2 and reversible and none grade 4 toxicity.


CONCLUSIONS
Icotinib monotherapy is an effective and well tolerated regimen for Chinese patients with NSCLC after the failure of chemotherapy. It is a promising agent and further study with icotinib in properly conducted trials with larger patient samples and other ethnic groups is warranted.
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Key Laboratory of Diagnosis and Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China.
Lan
L
Shao
Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
Beibei
B
Zhang
Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
Chunxiao
C
He
Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
Baochai
B
Lin
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Key Laboratory of Diagnosis and Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China.
Zhengbo
Z
Song
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Key Laboratory of Diagnosis and Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China.
Guangyuan
G
Lou
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Key Laboratory of Diagnosis and Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China.
Xinmin
X
Yu
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Key Laboratory of Diagnosis and Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China. Email: zyp@medmail.com.cn.
Yiping
Y
Zhang
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D043844:Crown Ethers / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib